Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s): ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

TSX:ATE - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Tsx

<< Previous

Bullboard Posts

Next >>

Comment by Daydream2on Nov 04, 2020 6:13pm

274 Views

Post# 31839592

RE:RE:RE:RE:RE:RE:RE:Tsx

Agree with you, thought with the caveat that I do not see stock pirice going anywhere until fall or even summertime of 2021. The only significance move will be based on a major buyout or full partnership. Meanwhile, braised yourself for successive money deficit quarterly filings.

quote=Duster340]patience, i do not see the stock going anywhere until early 2021. no institutional buyers will hold a penny stock at year end. however hope to see a bounce back to 40 after tax loss selling is done with retail investors taking a position at bargain basement prices.
glta[/quote]

<< Previous

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle